Results 51 to 60 of about 1,261,156 (366)

Indication and adverse event profiles of denosumab and zoledronic acid: based on U.S. FDA adverse event reporting system (FAERS)

Frontiers in Pharmacology, 2023
Objective: To investigate adverse events (AEs) associated with denosumab (Dmab) and zoledronic acid (ZA), compare their association strengths, and explore potential applications to provide clinical reference.Methods: We collected data from FAERS from ...
Si Su, Si Su, Liuqing Wu, Guibao Zhou, Lingling Peng, Huanzhe Zhao, Xiao Wang, Xiao Wang, Kuan Li   +8 more
doaj   +1 more source

Adverse event profiles of PCSK9 inhibitors alirocumab and evolocumab: Data mining of the FDA adverse event reporting system

British Journal of Clinical Pharmacology, 2022
Proprotein convertase subtilisin/kexin type (PCSK9) inhibitor is a new drug class approved for treating dyslipidemias. Herein, we aimed to investigate the safety profiles of PCSK9 inhibitors (alirocumab and evolocumab) using the Food and Drug ...
Chunmei Ji, Jinmei Bai, Jian-cheng Zhou, Y. Zou, Mingming Yu   +4 more
semanticscholar   +1 more source

Adverse event profiles of solvent-based and nanoparticle albumin-bound paclitaxel formulations using the Food and Drug Administration Adverse Event Reporting System

SAGE Open Medicine, 2019
Objectives: Paclitaxel is a highly effective antitumor agent with notable adverse events, including hypersensitivity reactions, peripheral neuropathy, arthralgia, myalgias, and neutropenia.
Misa Naganuma, Kohei Tahara, Shiori Hasegawa, Akiho Fukuda, Sayaka Sasaoka, Haruna Hatahira, Yumi Motooka, Satoshi Nakao, Ririka Mukai, Kouseki Hirade, Tomoaki Yoshimura, Takeshi Kato, Hirofumi Takeuchi, Mitsuhiro Nakamura   +13 more
doaj   +1 more source

SGLT-2 inhibitors and atrial fibrillation in the Food and Drug Administration adverse event reporting system

Cardiovascular Diabetology, 2021
Background Sodium glucose cotransporter-2 inhibitors (SGLT2i) reduce the risk of heart failure and new data show they can prevent atrial fibrillation (AF).
B. Bonora, E. Raschi, A. Avogaro, G. Fadini   +3 more
semanticscholar   +1 more source

Adverse Events Related to Off-Label Drugs Using Spontaneous Adverse Event Reporting Systems

Therapeutics and Clinical Risk Management, 2021
The purpose of this study was to investigate the adverse events (AEs) related to the use of off-label drugs.A cross-sectional study was carried out using available data pertaining to off-label drug were sourced from U.S. FDA spontaneous adverse drug reaction reporting database (FAERS) and Korea Adverse Event Reporting System database (KIDS-KD) for the ...
In-Wha Kim, Nayoung Han, Nayoung Han, Jung Mi Oh   +3 more
openaire   +5 more sources

Completeness of adverse drug reactions reports of the Saudi adverse event reporting system

Saudi Medical Journal, 2015
To assess completeness of reports in the Saudi Adverse Event Reporting System (SAERS), which is a part of the Saudi Food and Drug Authority pharmacovigilance system for monitoring the safety of medications.A cross-sectional study was conducted in Riyadh, Saudi Arabia using the reports that were received between December 2009 and June 2012 in the SAERS.
Waad H. Al-Kathiri, Hervé Le Louet, Hisham Aljadhey, Thamir M. Alshammari   +3 more
openaire   +3 more sources

Safety of Booster Doses of Coronavirus Disease 2019 (COVID-19) Vaccine in Pregnancy in the Vaccine Adverse Event Reporting System

Obstetrics and Gynecology, 2022
The safety profile of booster doses of coronavirus disease 2019 (COVID-19) vaccine is reassuring and comparable with that of primary COVID-19 vaccine in pregnant people.
P. Moro, C. Olson, Bicheng Zhang, P. Marquez, Penelope Strid   +4 more
semanticscholar   +1 more source

Automatically Recognizing Medication and Adverse Event Information From Food and Drug Administration’s Adverse Event Reporting System Narratives

JMIR Medical Informatics, 2014
BackgroundThe Food and Drug Administration’s (FDA) Adverse Event Reporting System (FAERS) is a repository of spontaneously-reported adverse drug events (ADEs) for FDA-approved prescription drugs.
Polepalli Ramesh, Balaji, Belknap, Steven M, Li, Zuofeng, Frid, Nadya, West, Dennis P, Yu, Hong   +5 more
doaj   +1 more source

Musculoskeletal Adverse Events Associated with PCSK9 Inhibitors: Disproportionality Analysis of the FDA Adverse Event Reporting System [PDF]

Cardiovascular Therapeutics, 2022
Background. Some studies suggest that potential safety issues about PCSK9 inhibitors have not been sufficiently explored in clinical trials, including musculoskeletal adverse events (MAEs). Objective. To examine the association between use of PCSK9 inhibitors with and without concurrent statins and risk of MAEs. Patients and Methods.
Lingqing Ding, Congqin Chen, Yongkuan Yang, Jie Fang, Longxing Cao, Yige Liu   +5 more
openaire   +3 more sources

The Absurdity of Death Estimates Based on the Vaccine Adverse Event Reporting System [PDF]

arXiv, 2022
We demonstrate from first principles a core fallacy employed by a coterie of authors who claim that data from the Vaccine Adverse Reporting System (VAERS) show that hundreds of thousands of U.S. deaths are attributable to COVID vaccination.
arxiv